OncoMatch/Clinical Trials/NCT05846750
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
Is NCT05846750 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Obinutuzumab and lenalidomide for marginal zone lymphoma.
Treatment: Obinutuzumab · lenalidomide — This is a prospective, multicenter clinical study that will enroll 59 patients with relapsed and refractory (R/R) MZL. The study is designed to evaluate the efficacy and safety of the combination of obinutuzumab and lenalidomide in the treatment of relapsed and refractory marginal zone lymphoma (MZL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Endocrine / hormonal
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic lymphoma therapy
Prior treatment with at least one line of systemic lymphoma including prior immunotherapy or chemoimmunotherapy
Cannot have received: lenalidomide (lenalidomide)
Exception: not refractory or resistant
Patients who are refractory or resistant to lenalidomide
Cannot have received: obinutuzumab (obinutuzumab)
Exception: not refractory or resistant
Patients who are refractory or resistant to obinutuzumab
Cannot have received: thalidomide (thalidomide)
Previous ≥ Grade 3 allergic reactions/Hypersensitivity to thalidomide
Lab requirements
Blood counts
Hemoglobin ≥ 7 g/dL; Absolute neutrophil count ≥ 1.0 × 10^9/L; Platelet count ≥ 50 x 10^9/L
Kidney function
Creatinine clearance ≥ 30 mL/min
Liver function
Glutathione transaminase(AST) or glutathione aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN); Serum bilirubin ≤ 2 × ULN (≤ 3 × ULN in patients with Gilbert's syndrome)
Adequate blood function... Hemoglobin ≥ 7 g/dL; Absolute neutrophil count ≥ 1.0 × 10^9/L; Platelet count ≥ 50 x 10^9/L; Creatinine clearance ≥ 30 mL/min; Glutathione transaminase(AST) or glutathione aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN); Serum bilirubin ≤ 2 × ULN (≤ 3 × ULN in patients with Gilbert's syndrome)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05846750 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior lenalidomide, obinutuzumab, thalidomide disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages